ReviewBioMed research international2016
Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer.
Review in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 72 citations in OpenAlex.
- Development of a clinical prediction model to guide the selective use of SPECT/CT in papillary thyroid cancer.Quantitative imaging in medicine and surgery · 2026Article
- Radioiodine Exhalation Following Oral I-131 Administration in a Mouse Model.Biomedicines · 2025Article
- Review
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.Oncogene · 2024Article
- Evaluation of Single Dose and Fractionated Dose of I-131 Radiolabeled Nanoparticles for Triple-Negative Breast Cancer Treatment.Biomedicines · 2023Article
- The Role of Molecular Imaging in Personalized Medicine.Journal of personalized medicine · 2023Review
- Production Review of Accelerator-Based Medical Isotopes.Molecules (Basel, Switzerland) · 2022Review
- Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents.Pharmaceutics · 2022Review
- Simultaneous multi-nuclide imaging via double-photon coincidence method with parallel hole collimators.Scientific reports · 2021Article
- Current State of Breast Cancer Diagnosis, Treatment, and Theranostics.Pharmaceutics · 2021Review
- Theranostic Advances in Breast Cancer in Nuclear Medicine.International journal of molecular sciences · 2021Review
- AhR Antagonist Promotes Differentiation of Papillary Thyroid CancerFrontiers in pharmacology · 2021Article
- Theranostic Terbium Radioisotopes: Challenges in Production for Clinical Application.Frontiers in medicine · 2021Review
- Crosstalk Between Abnormal TSHR Signaling Activation and PTEN/PI3K in the Dedifferentiation of Thyroid Cancer Cells.Frontiers in oncology · 2021Article
- Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening.Cancers · 2020Article
- Theranostics: is it really a revolution? Evaluating a new term in medicine.Medicine, health care, and philosophy · 2019Article
- Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019Review
- Deep-dose: a voxel dose estimation method using deep convolutional neural network for personalized internal dosimetry.Scientific reports · 2019Article
- Perspectives in Radiomics for Personalized Medicine and Theranostics.Nuclear medicine and molecular imaging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Molecular imaging based personalized therapy has been a fascinating concept for individualized therapeutic strategy, which is able to attain the highest efficacy and reduce adverse effects in certain patients. Theranostics, which integrates diagnostic testing to detect molecular targets for particular therapeutic modalities, is one of the key technologies that contribute to the success of personalized medicine. Although the term "theranostics" was used after the second millennium, its basic principle was applied more than 70 years ago in the field of thyroidology with radioiodine molecular imaging. Differentiated thyroid cancer, which arises from follicular cells in the thyroid, is the most common endocrine malignancy, and theranostic radioiodine has been successfully applied to diagnose and treat differentiated thyroid cancer, the applications of which were included in the guidelines published by various thyroid or nuclear medicine societies. Through better pathophysiologic understanding of thyroid cancer and advancements in nuclear technologies, theranostic radioiodine contributes more to modern tailored personalized management by providing high therapeutic effect and by avoiding significant adverse effects in differentiated thyroid cancer. This review details the inception of theranostic radioiodine and recent radioiodine applications for differentiated thyroid cancer management as a prototype of personalized medicine based on molecular imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.